Cancer immunotherapy by targeting of immune checkpoint molecules has been a research ‘hot-spot’ in recent years. Nivolumab, a human monoclonal antibody targeting PD-1, has been widely used clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback